Liposomal amphotericin-B (AmBisome) is now becoming first choice for the treatment of visceral leishmaniasis (kala-azar) patients due to high efficacy and less toxicity. The reported incidence of hypersensitivity reactions to liposomal amphotericin-B (AmBisome), especially during therapy, is very rare. We report two patients with kala-azar: one developed breathing difficulties and hypotension f...

Visceral leishmaniasis (VL) is caused by the protozoan parasite Leishmania donovani and transmitted by the bite of infected sandfly Phlebotomus argentipes. The protozoa is obliged intracellularly and causes a wide spectrum of clinical syndromes: VL ('kala azar'), cutaneous leishmaniasis and mucocutaneous leishmaniasis (espundia). Kala azar is the most aggressive form and if untreated causes hig...

In our present issue we publish two articles in which the value of a complement-fixation test in early diagnosis of kala-azar is stressed. The antigen used is that of Witebsky, Klingenstein and Kuhn prepared from the tubercle bacillus, and originally intended for complement-fixation tests in tuberculosis. In tuberculosis, however, the results are very poor. Work in South America, however, revea...

İş sağlığı ve güvenliğinin en temel amacı iş kazaları meslek hastalıklarını önlemek olup tüm dünyada yapılan bilimsel hukuki çalışmalar bu amaç doğrultusundadır. Yapılan işe bağlı olarak ortaya çıkan risk tehlikelerin kontrol altına alınması kazalarının önlenmesi için büyük unsurdur. gerçekleşebilme potansiyellerinin araştırılmasındaki gösterge olan ramak kala olayların ne olduğu bilinmelidir. ...

background: visceral leishmaniasis (vl) has strong links with poverty, substantial medical and veterinary impacts. this review aimed to focus in studies published during 1994-2016 on vl in southeastern iran. methods : the present review is based on expert knowledge and historical studies published during the past 23 yr (1994-2016) on vl in southeastern iran. in addition, related literature foun...

A pentavalent antimony compound (Sdt. 561, solustibosan, antimony-v-hexonate, containing 20 mg. of antimony per c.cm. of solution) , that made a stable solution and could be given intramuscularly, was first introduced b) Prof. H. Schmidt, the pioneer worker on pent*1' valent antimony compounds. Kikuth and Schmidt (1938) found that this compound possessed a marked curative action in the le*,' ma...

Fig 3 and Fig 4 are incorrect. The authors have provided corrected versions here. Copyright: © 2015 Ramesh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.